Nasdaq OMX

Oxford Immunotec

Del

Oxford Immunotec Announces Availability of the T-SPOT.PRT Test in the United States

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2015-12-03 13:00 CET (GLOBE NEWSWIRE) --

Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the availability of the T-SPOT®.PRTtest in the United States. The panel of reactive T cells (PRT) test assesses a solid organ transplant candidate’s T cell response to foreign tissue, referred to as alloreactivity. The T-SPOT.PRTtest is now available as a laboratory developed test from the Company's CLIA-certified and CAP accredited service laboratory.

Alloreactivity is the body’s reaction to foreign tissue. In transplant, understanding the likelihood of a rejection event is an important factor in patient management. A T cell immune response to the donated organ can lead to T cell mediated rejection (TCMR), which is a complication detrimental to the survival of the transplanted organ. The T-SPOT.PRTtest measures a transplant candidate’s T cell mediated response to cells representing the potential donor population. This test may help clinicians identify patients at increased risk of TCMR, which in turn may guide decisions regarding immunosuppressive therapies.

"We are pleased to make available the T-SPOT.PRTtest in the US this year as anticipated," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "While we are enthusiastic about the potential clinical utility and economic value that the T-SPOT.PRTtest may provide in transplant medicine, we are taking a measured approach to market introduction as we await the results of our PROTECT clinical trial. We expect full commercial launch in 2017 based on results from PROTECT."

The T-SPOT.PRTtest leverages Oxford Immunotec's proprietary T-SPOT technology platform and will be performed at Oxford Diagnostic Laboratories in Memphis, TN. The T-SPOT.PRTtest builds on Oxford Immunotec's capabilities in T cell measurement technology, and is the second in a series of planned new products intended to help transplant patients and physicians manage immune regulated conditions.

The T-SPOT.PRTtest is pending approval in California, New York and Florida.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. With this release, the Company now has three products available. The Company's first product is the T-SPOT.TBtest, which is used to test for tuberculosis infection. The T-SPOT.TBtest has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMVtest and this T-SPOT.PRTtest are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found atwww.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec@westwicke.com

Information om Nasdaq OMX

Nasdaq OMX
Nasdaq OMX
Nikolaj Plads 6
1007 København K

+45 3377 0377http://globenewswire.com